TMCnet News
Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical MeetingsAimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut allergy during poster sessions at two upcoming medical meetings. ACAAI: At the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place October 26-30, 2017, in Boston, Aimmune will present:
Aimmune will also host a Corporate Symposium, "From Diagnosis to Potential Future Oral Immnotherapeutic Options: Understanding the Burden and Risk of Avoidance in Peanut Allergy," on Friday, October 27. PAAM: At the European Academy of Allergy and Clinical Immunology's Pediatric Allergy and Asthma Meeting (PAAM), taking place October 26-28, 2017, in London, Aimmune will present:
Aimmune will also host a Corporate Symposium, "Peanut Allergy: Impact, Treatment and Defining Success," on Friday, October 27. About Aimmune Therapeutics Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, is developing treatments for life-threatening food allergies. Aimmune's Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA's Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171019005406/en/ |